182 related articles for article (PubMed ID: 30508308)
41. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
De Clercq E
Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
[TBL] [Abstract][Full Text] [Related]
42. Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks: Post hoc Analyses of AMBER and EMERALD.
Dunn K; Baugh B; Bejou N; Luo D; Campbell J; Seyedkazemi S; Anderson D
J Int Assoc Provid AIDS Care; 2022; 21():23259582221088202. PubMed ID: 35466761
[TBL] [Abstract][Full Text] [Related]
43. Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study.
Spinner CD; Schulz S; Bauer U; Schneider J; Bobardt J; Von Werder A; Schmid RM; Zink A; Wolf E; Iakoubov R
Antivir Ther; 2018; 23(7):629-632. PubMed ID: 30281025
[TBL] [Abstract][Full Text] [Related]
44. Pharmacology of Symtuza
Curran A; Navarro J
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Dec; 36 Suppl 2():10-16. PubMed ID: 30545466
[TBL] [Abstract][Full Text] [Related]
45. A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.
Huhn GD; Tebas P; Gallant J; Wilkin T; Cheng A; Yan M; Zhong L; Callebaut C; Custodio JM; Fordyce MW; Das M; McCallister S
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):193-200. PubMed ID: 27753684
[TBL] [Abstract][Full Text] [Related]
46. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Gallant J; Brunetta J; Crofoot G; Benson P; Mills A; Brinson C; Oka S; Cheng A; Garner W; Fordyce M; Das M; McCallister S;
J Acquir Immune Defic Syndr; 2016 Nov; 73(3):294-298. PubMed ID: 27171740
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Llaves S; Fernandez-Magdaleno T; Espinosa N; Viciana P; Lopez-Cortes LF
J Antimicrob Chemother; 2017 Mar; 72(3):816-819. PubMed ID: 27999051
[TBL] [Abstract][Full Text] [Related]
48. Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418.
Cabello-Úbeda A; Baeza AG; García JT; de La Fuente Moral S; Mena MN; Martínez AP; Micán R; Górgolas M; Tascón GC; de Santiago AD; Morerno JS; Crestelo DR; Arenzana CB; Serna JIB; Almirón MD; Cano J; Esteban H; Pérez-Valero I
Open Forum Infect Dis; 2022 Sep; 9(9):ofac345. PubMed ID: 36147597
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals.
Begley R; Das M; Zhong L; Ling J; Kearney BP; Custodio JM
J Acquir Immune Defic Syndr; 2018 Aug; 78(4):465-472. PubMed ID: 29649076
[TBL] [Abstract][Full Text] [Related]
50. Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Álvarez H; Mariño A; Valcarce N; García-González J; Díaz-Cambre H; Llibre JM
Infection; 2019 Feb; 47(1):115-119. PubMed ID: 30145772
[TBL] [Abstract][Full Text] [Related]
51. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136
[TBL] [Abstract][Full Text] [Related]
52. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
53. An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Giacomet V; Cossu MV; Capetti AF; Zuccotti G; Rizzardini G
Expert Opin Pharmacother; 2019 Feb; 20(3):269-276. PubMed ID: 30586314
[TBL] [Abstract][Full Text] [Related]
54. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).
Podzamczer D; Micán R; Tiraboschi J; Portilla J; Domingo P; Llibre JM; Ribera E; Vivancos MJ; Morano L; Masiá M; Gómez C; Fanjul F; Payeras A; Inciarte A; Estrada V; Rivero A; Castro Á; Bernal E; Vinuesa D; Knobel H; Troya J; Macías J; Montero M; Sanz J; Navarro-Alcaraz A; Caicedo A; Fernández G; Martínez E; Moreno S
Open Forum Infect Dis; 2022 Mar; 9(3):ofab595. PubMed ID: 35237700
[TBL] [Abstract][Full Text] [Related]
55. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
Crauwels HM; Osiyemi O; Zorrilla C; Bicer C; Brown K
HIV Med; 2019 May; 20(5):337-343. PubMed ID: 30873741
[TBL] [Abstract][Full Text] [Related]
56. First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Waalewijn H; Szubert AJ; Wasmann RE; Wiesner L; Chabala C; Bwakura-Dangarembizi M; Makumbi S; Nangiya J; Mumbiro V; Mulenga V; Musiime V; Monkiewicz LN; Griffiths AL; Bamford A; Doerholt K; Denti P; Burger DM; Gibb DM; McIlleron HM; Colbers A;
Clin Infect Dis; 2023 Sep; 77(6):875-882. PubMed ID: 37315296
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot ER; Cerrone M; Challenger E; Else L; Amara A; Bisdomini E; Khoo S; Owen A; Boffito M
J Antimicrob Chemother; 2019 Jan; 74(1):149-156. PubMed ID: 30272231
[TBL] [Abstract][Full Text] [Related]
58. Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Gantner P; Hessamfar M; Souala MF; Valin N; Simon A; Ajana F; Bouvet E; Rouveix E; Cotte L; Bani-Sadr F; Hustache-Mathieu L; Lebrette MG; Truchetet F; Galempoix JM; Piroth L; Pellissier G; Muret P; Rey D;
Clin Infect Dis; 2020 Feb; 70(5):943-946. PubMed ID: 31804669
[TBL] [Abstract][Full Text] [Related]
59. Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
Kakuda TN; Van De Casteele T; Petrovic R; Neujens M; Salih H; Opsomer M; Hoetelmans RM
Antivir Ther; 2014; 19(6):597-606. PubMed ID: 24964392
[TBL] [Abstract][Full Text] [Related]
60. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Dunn K; Bushen J; Luo D; Cai J; Simonson RB; Anderson D
HIV Med; 2023 Mar; 24(3):279-289. PubMed ID: 36912173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
